Connor, Clark & Lunn Investment Management (CC&L)’s Repros Therapeutics Inc. RPRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-37,500	Closed	-$45K	–	1068
2017 Q1	$45K	Sell	37,500 -200	-0.5%	-$250	﹤0.01%	876
2016 Q4	$50K	Sell	37,700 -1,000	-3%	-$1.74K	﹤0.01%	858
2016 Q3	$81K	Hold	38,700	–	–	﹤0.01%	786
2016 Q2	$62K	Hold	38,700	–	–	﹤0.01%	824
2016 Q1	$38K	Hold	38,700	–	–	﹤0.01%	809
2015 Q4	$47K	Buy	+38,700	New	+$124K	﹤0.01%	790

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RPRX Position: Q2 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Repros Therapeutics Inc. (RPRX) in Q2 2017, closing a stake of 37,500 shares — an estimated $45K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RPRX in Q4 2015 and held it in 6 quarters. The position peaked at $81K in Q3 2016. 29 funds tracked by Wall St. Rank hold RPRX as of Q2 2017.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Repros Therapeutics Inc. position as of Q2 2017 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 37,500 Repros Therapeutics Inc. shares in Q2 2017, an estimated $45K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Repros Therapeutics Inc. in Q4 2015 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Repros Therapeutics Inc. position peaked at $81K in Q3 2016.
29 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2017, filed 14 Aug 2017.